Abbott India（500488）株式概要アボット・インディア・リミテッドは、その子会社とともにインドで製薬会社として事業を展開している。 詳細500488 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績4/6財務の健全性6/6配当金6/6報酬収益は年間9.6%増加すると予測されています 過去5年間の収益は年間17.4%増加しました。 1.9%の高配当で安定した配当金を支払う リスク分析リスクチェックの結果、500488 、リスクは検出されなかった。すべてのリスクチェックを見る500488 Community Fair Values Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW470,065 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA470,065 investors already sharing narrativesYour Fair Value₹Current Price₹27.62k18.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0105b2016201920222025202620282031Revenue ₹104.8bEarnings ₹23.5bAdvancedSet Fair ValueView all narrativesAbbott India Limited 競合他社Glenmark PharmaceuticalsSymbol: NSEI:GLENMARKMarket cap: ₹654.7bAlkem LaboratoriesSymbol: NSEI:ALKEMMarket cap: ₹651.6bGlaxoSmithKline PharmaceuticalsSymbol: BSE:500660Market cap: ₹451.4bAjanta PharmaSymbol: NSEI:AJANTPHARMMarket cap: ₹451.4b価格と性能株価の高値、安値、推移の概要Abbott India過去の株価現在の株価₹27,617.4552週高値₹33,849.9552週安値₹25,164.00ベータ0.0561ヶ月の変化0.35%3ヶ月変化-1.14%1年変化-16.90%3年間の変化16.75%5年間の変化46.43%IPOからの変化4,745.17%最新ニュースお知らせ • 4hAbbott India Limited Announces Board ChangesAbbott India Limited announced contribution of Mr. Munir Shaikh outgoing as Chairman of the Company. Mr. Sudarshan Jain had been appointed as Chairman of the Board with effect from August 13, 2026.お知らせ • Aug 04Abbott India Limited to Report Q1, 2027 Results on Aug 12, 2026Abbott India Limited announced that they will report Q1, 2027 results on Aug 12, 2026Reported Earnings • Jul 22Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹69.3b (up 8.1% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 20+ 2 more updatesAbbott India Limited Announces Retirement of Munir Shaikh as DirectorAbbott India Limited announced that Mr. Munir Shaikh, who retires by rotation at this Annual General Meeting and who has not offered himself for re-appointment, be and is hereby not re-appointed as a Director of the Company and the vacancy, so created, be not filled.Upcoming Dividend • Jul 17Upcoming dividend of ₹656 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 12 September 2026. Payout ratio is a comfortable 72% and the cash payout ratio is 87%. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).Declared Dividend • May 14Dividend increased to ₹525Dividend of ₹525 is 11% higher than last year. Ex-date: 24th July 2026 Payment date: 12th September 2026 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (71% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 31% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.最新情報をもっと見るRecent updatesお知らせ • 4hAbbott India Limited Announces Board ChangesAbbott India Limited announced contribution of Mr. Munir Shaikh outgoing as Chairman of the Company. Mr. Sudarshan Jain had been appointed as Chairman of the Board with effect from August 13, 2026.お知らせ • Aug 04Abbott India Limited to Report Q1, 2027 Results on Aug 12, 2026Abbott India Limited announced that they will report Q1, 2027 results on Aug 12, 2026Reported Earnings • Jul 22Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹69.3b (up 8.1% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 20+ 2 more updatesAbbott India Limited Announces Retirement of Munir Shaikh as DirectorAbbott India Limited announced that Mr. Munir Shaikh, who retires by rotation at this Annual General Meeting and who has not offered himself for re-appointment, be and is hereby not re-appointed as a Director of the Company and the vacancy, so created, be not filled.Upcoming Dividend • Jul 17Upcoming dividend of ₹656 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 12 September 2026. Payout ratio is a comfortable 72% and the cash payout ratio is 87%. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).Declared Dividend • May 14Dividend increased to ₹525Dividend of ₹525 is 11% higher than last year. Ex-date: 24th July 2026 Payment date: 12th September 2026 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (71% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 31% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 13Abbott India Limited announces Annual dividend, payable on September 12, 2026Abbott India Limited announced Annual dividend of INR 525.0000 per share payable on September 12, 2026, ex-date on July 24, 2026 and record date on July 24, 2026.お知らせ • May 12Abbott India Limited, Annual General Meeting, Aug 13, 2026Abbott India Limited, Annual General Meeting, Aug 13, 2026.Reported Earnings • May 12Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹72.2b (up 13% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • May 02Abbott India Limited to Report Q4, 2026 Results on May 11, 2026Abbott India Limited announced that they will report Q4, 2026 results on May 11, 2026Reported Earnings • Feb 13Third quarter 2026 earnings released: EPS: ₹177 (vs ₹170 in 3Q 2025)Third quarter 2026 results: EPS: ₹177 (up from ₹170 in 3Q 2025). Revenue: ₹17.9b (up 11% from 3Q 2025). Net income: ₹3.76b (up 4.2% from 3Q 2025). Profit margin: 21% (down from 22% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 04Abbott India Limited to Report Q3, 2026 Results on Feb 12, 2026Abbott India Limited announced that they will report Q3, 2026 results on Feb 12, 2026New Risk • Nov 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Dividend is not well covered by cash flows (100% cash payout ratio).Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹195 (vs ₹169 in 2Q 2025)Second quarter 2026 results: EPS: ₹195 (up from ₹169 in 2Q 2025). Revenue: ₹18.3b (up 12% from 2Q 2025). Net income: ₹4.15b (up 16% from 2Q 2025). Profit margin: 23% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 14% per year.お知らせ • Oct 29Abbott India Limited to Report Q2, 2026 Results on Nov 06, 2025Abbott India Limited announced that they will report Q2, 2026 results on Nov 06, 2025Board Change • Sep 10Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 05Abbott India Limited to Report Q1, 2026 Results on Aug 12, 2025Abbott India Limited announced that they will report Q1, 2026 results on Aug 12, 2025Reported Earnings • Jul 24Full year 2025 earnings released: EPS: ₹666 (vs ₹565 in FY 2024)Full year 2025 results: EPS: ₹666 (up from ₹565 in FY 2024). Revenue: ₹64.1b (up 9.6% from FY 2024). Net income: ₹14.1b (up 18% from FY 2024). Profit margin: 22% (up from 21% in FY 2024). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 7 Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 21% per year.Upcoming Dividend • Jul 18Upcoming dividend of ₹475 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 12 September 2025. Payout ratio is a comfortable 71% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.8%).Board Change • Jun 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Additional Non-Executive Director Alison Davies was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • May 17Dividend increased to ₹475Dividend of ₹475 is 16% higher than last year. Ex-date: 25th July 2025 Payment date: 12th September 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not adequately covered by cash flows (91% cash payout ratio). The dividend has increased by an average of 37% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 24% over the next 2 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 16+ 1 more updateAbbott India Limited, Annual General Meeting, Aug 13, 2025Abbott India Limited, Annual General Meeting, Aug 13, 2025.Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹666 (vs ₹565 in FY 2024)Full year 2025 results: EPS: ₹666 (up from ₹565 in FY 2024). Revenue: ₹66.8b (up 14% from FY 2024). Net income: ₹14.1b (up 18% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.お知らせ • May 09Abbott India Limited to Report Fiscal Year 2025 Results on May 15, 2025Abbott India Limited announced that they will report fiscal year 2025 results on May 15, 2025Price Target Changed • May 07Price target increased by 8.8% to ₹32,470Up from ₹29,839, the current price target is an average from 7 analysts. New target price is 7.3% above last closing price of ₹30,260. Stock is up 17% over the past year. The company is forecast to post earnings per share of ₹656 for next year compared to ₹565 last year.お知らせ • Apr 19Abbott India Limited Appoints Maithilee Mistry as the Key Managerial Personnel, Effective May 6, 2025Abbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors at its Meeting held on April 18, 2025, approved the appointment of Ms. Maithilee Mistry as the Key Managerial Personnel of the Company effective May 6, 2025. Maithilee Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years, having held leadership roles in various Multinational companies. Previously Maithilee held a role of CFO for Sanofi Consumer Healthcare India Limited. Prior to that, she worked with Dow chemical in USA as global Funding Director, responsible for all aspects of corporate funding and banking relations. Before relocating to USA, she was Finance Director for Dow Chemical, India subcontinent region. Maithilee has also served as Board member in various companies including a public listed entity and other joint ventures in India. Before Joining Dow, she has also held leadership positions with Omya and Cognis, European multinational companies, leading teams in India and Southwest Asia with responsibilities for Finance, HR, Legal and IT. She is a qualified Chartered Accountant who started her career with Deloitte (India) as a member of statutory audit team. Ms. Maithilee Mistry is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company.お知らせ • Apr 17Abbott India Limited Announces the Resignation of Ms. Namita Shah - Associate Director -New Product Introduction and Therapy Area Strategy of the Company, Effective from April 15, 2025Abbott India Limited announced the resignation of Ms. Namita Shah - Associate Director -New Product Introduction and Therapy Area Strategy of the Company, effective close of business hours of April 15, 2025, to pursue opportunities outside the Company.お知らせ • Apr 01Abbott India Limited Appoints Devesh Choudhari as Director - Finance, Effective April 1, 2025Abbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Devesh Choudhari as Director - Finance effective April 1, 2025. He will be part of the Senior Management team of the Company. Mr. Devesh Choudhari is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company. Devesh Choudhari is a seasoned finance professional specializing in Finance, Accounting, Structuring, M&A, Fundraising, and Controls and has 18 years of experience. He brings a wealth of knowledge and a proven track record in leading complex financial projects. In his most recent role, Devesh joined Perfect Day, to lead their Indian manufacturing business following the acquisition of Sterling Biotech. As CFO, he played a key role in driving the business performance and contributed to the groundwork for a $100 million greenfield project currently under construction. Devesh actively contributed to the strategic sale and played a pivotal role in forming the joint venture with the Zydus group, later serving as its CFO. Prior to this, Devesh spent nearly a decade at the Piramal Group, gaining hands-on experience in multi-segment, multi-location manufacturing setups, as well as equity raises totaling over $1.5 billion. He significantly contributed to the $4 billion DHFL acquisition by Piramal and efficiently managed the integration of its financial operations. Earlier in his career, he worked with Deloitte in the Assurance function, handling leading FMCG, Chemical, and pharmaceutical companies. Devesh is a qualified Chartered Accountant and has done a Diploma in International Financial Reporting Standards (IFRS).お知らせ • Mar 26Abbott India Limited Announces Resignation of Jyoti Saraph, Director Finance, with Effect from June 23, 2025Abbott India Limited informed that Ms. Jyoti Saraph, Director Finance, has tendered her resignation from employment of the Company with effect from the close of business hours of June 23, 2025, to pursue opportunities outside the Company.Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹170 (vs ₹146 in 3Q 2024)Third quarter 2025 results: EPS: ₹170 (up from ₹146 in 3Q 2024). Revenue: ₹16.1b (up 12% from 3Q 2024). Net income: ₹3.61b (up 16% from 3Q 2024). Profit margin: 22% (in line with 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 21% per year.お知らせ • Feb 03Abbott India Limited Announces Board ChangesAbbott India Limited informed that Mr. Kunal Chowdhury - Commercial Director - GI Businesses has been promoted to another affiliate of Abbott in India effective February 1, 2025. Accordingly,he has served his role as Commercial Director - GI Businesses with Abbott India Limited until January 31, 2025.お知らせ • Jan 28Abbott India Limited to Report Q3, 2025 Results on Feb 05, 2025Abbott India Limited announced that they will report Q3, 2025 results on Feb 05, 2025お知らせ • Jan 21Abbott India Limited Announces Kunal Chowdhury - Commercial Director - GI Businesses, to Serve Until January 31, 2025Abbott India Limited informed that Mr. Kunal Chowdhury - Commercial Director - GI Businesses has been promoted to another affiliate of Abbott in India effective February 1, 2025. He will serve his role as Commercial Director - GI Businesses with Abbott India Limited until January 31, 2025.お知らせ • Jan 16Abbott India Limited Appoints Anuj Mehra as Commercial Director - Neurolife, Gennext and Vaccines, Effective February 1, 2025Abbott India Limited announced that Mr. Anuj Mehra, Senior Management Personnel, has been designated as Commercial Director - NeuroLife, GenNext and Vaccines effective February 1, 2025. Anuj is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company. Anuj Mehra has over 26 years of experience in Sales and Marketing in companies of diverse sizes. He has held leadership roles in Sales, Marketing, and Strategic planning. Anuj joined Abbott in 2018 as Head of Marketing for NeuroLife. Since then, Anuj has grown within the system by successfully managing various roles as Associate Director for Neurolife and is currently working as Associate Director of GenNext. Anuj has been instrumental in building a brand portfolio and driving business with robust strategic and operational excellence. Anuj, with his diverse experience, is able to think through and leverage growth opportunities in the operating segment by devising market-shaping initiatives. He has the ability to build robust business models to support business strategy and execute them. In the past, Anuj has worked with organizations like Sandoz, Ranbaxy, UCB, and Novartis. Anuj has a Bachelor's degree in Science from Delhi University and a Post Graduate Diploma in Business Management from SVKM's Narsee Monjee Institute of Management Studies (NMIMS).お知らせ • Jan 03Abbott India Limited Announces Change of Commercial DirectorAbbott India Limited announced that Murari Ranganathan, Commercial Director - Women's Health, Metabolics and International Business, has tendered his resignation from employment of the Company with effect from close of business hours of February 25, 2025, to pursue opportunities outside the Company. Prithwish Kumar Banerji has been appointed as Commercial Director - Women's Health, Metabolics and International Business with effect from January 3, 2025. In accordance with the SEBI Listing Regulations, Prithwish will be considered as Senior Management Personnel of the Company. Prithwish has close to 28 years of experience in a Commercia role. He joins Abbott from Cipla, where he was a member of the Cipla Leadership Group. He was the designated Vice President and Vertical head for their respiratory portfolio of Nebulization and Immunotherapy. Prithwish presents a blended experience in Sales, Marketing, Strategic Business Planning and Execution. Prior to Cipla, Prithwish worked across Pharma MNCs and FMCG organizations like Unilever and GSK Consumer Healthcare. In the past, Prithwish had a small stint with Abbott Diabetes Care business as National Sales Manager. Prithwish has proven success in establishing new entrants in the Indian Pharmaceutical Market, Patent Product Launches, and Go-to-Market models, creating winners across the industry spectrum - Pharmaceuticals, OTC/OTX, and FMCG. Prithwish is a Honors graduate in Geology from St Xavier's College, Ranchi, and holds an Executive Management Program in Management from IIM Lucknow.お知らせ • Dec 19+ 1 more updateAbbott India Limited Announces Resignation of Sridhar Kadangode as Whole Time Director and DirectorAbbott India Limited announced that Mr. Sridhar Kadangode, has tendered his resignation as Whole Time Director and Director of the Company, effective close of business hours of December 16, 2024, which has been accepted by the Board of Directors.Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: ₹169 (vs ₹147 in 2Q 2024)Second quarter 2025 results: EPS: ₹169 (up from ₹147 in 2Q 2024). Revenue: ₹16.9b (up 13% from 2Q 2024). Net income: ₹3.59b (up 15% from 2Q 2024). Profit margin: 21% (in line with 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 07Abbott India Limited Appoints Mr. Sridhar Kadangode as an Additional Director and as the Whole Time Director of the CompanyAbbott India Limited Approved the appointment of Mr. Sridhar Kadangode (DIN: 06715478) as an Additional Director of the Company and as the Whole Time Director of the Company for a period of 2 (two) years with effect from November 7, 2024. Sridhar has overall 25 years of diversified experience in Finance and other functions and joined Abbott in 2014. Prior to being promoted as Group Finance Director and Chief Financial Officer of the Company in July 2023, Sridhar was the Director - Finance of the Company responsible for finance, demand planning and business compliance function. Under his leadership, the Company recorded a strong financial performance through the pandemic, both in topline and bottom line and continued to focus on future growth. He has also redesigned the 5-year strategic financial plan for the Company. He drove a leveraged PL for the Company which resulted in Topline growing higher than market and a significantly improved bottom line for 2023-24. Sridhar started his career with Abbott as Director Finance, ANI and was part of the Core Management Team which evolved the Path to Profitability for the Nutrition business for South Asia which included achieving significant improvement in bottom line. He has led some of the key business projects linked to business response during Demonetization, Distributor Optimization and Cost Leadership Initiatives. Sridhar started his professional journey with Britannia Industries and then moved to Group Danone where he handled multiple assignments overseas (Singapore, US, Malaysia, South Africa) before relocating back to India in 2011 and in these companies, he was responsible for Finance, Supply Chain and Procurement functions. His key accomplishments with Danone include Reorganization of Business Model, Implementation of Supply Chain efficiency projects and transformation of Finance function into a key business partner in driving the business. Sridhar is a qualified Chartered Accountant from Institute of Chartered Accountants of India and Cost Accountant from Institute of Cost Accountants of India.お知らせ • Oct 29Abbott India Limited to Report Q2, 2025 Results on Nov 07, 2024Abbott India Limited announced that they will report Q2, 2025 results on Nov 07, 2024お知らせ • Aug 09Abbott India Limited Approves Final Dividend for Financial Year Ended March 31, 2024Abbott India Limited at its AGM held on August 08, 2024, approved to declare a final dividend of INR 410/- per Equity Share for the financial year ended March 31, 2024.お知らせ • Jul 30Abbott India Limited to Report Q1, 2025 Results on Aug 07, 2024Abbott India Limited announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • Jul 17Abbott India Limited Announces Resignation of Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife, Effective October 16, 2024Abbott India Limited informed that Mr. Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife has tendered his resignation from employment of the Company with effect from October 16, 2024, for personal reasons. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective October 16, 2024.Board Change • Jul 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 14Full year 2024 earnings released: EPS: ₹565 (vs ₹447 in FY 2023)Full year 2024 results: EPS: ₹565 (up from ₹447 in FY 2023). Revenue: ₹58.5b (up 9.4% from FY 2023). Net income: ₹12.0b (up 27% from FY 2023). Profit margin: 21% (up from 18% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 8 Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year.Upcoming Dividend • Jul 12Upcoming dividend of ₹410 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 07 September 2024. Payout ratio is a comfortable 73% and this is well supported by cash flows. Trailing yield: 1.5%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%).お知らせ • Jun 13Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024Abbott India Limited announced resignation of Ms. Sabina Ewing as Director of the Company, effective close of business hours of June 12, 2024, due to her pre-occupation with other professional commitments.お知らせ • May 12Abbott India Limited, Annual General Meeting, Aug 08, 2024Abbott India Limited, Annual General Meeting, Aug 08, 2024.Reported Earnings • May 11Full year 2024 earnings released: EPS: ₹565 (vs ₹447 in FY 2023)Full year 2024 results: EPS: ₹565 (up from ₹447 in FY 2023). Revenue: ₹61.0b (up 14% from FY 2023). Net income: ₹12.0b (up 27% from FY 2023). Profit margin: 20% (up from 18% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 18% per year.Declared Dividend • May 11Dividend increased to ₹410Dividend of ₹410 is 26% higher than last year. Ex-date: 19th July 2024 Payment date: 7th September 2024 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (40% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 34% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 35% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 11Abbott India Limited Recommends Final Dividend for the Year Ended March 31, 2024, Payable on or After August 13, 2024Abbott India Limited recommended payment of final dividend of INR 410/- per equity share of INR 10/- each for the year ended March 31, 2024, subject To Approve the Shareholders at the ensuing Eightieth Annual General Meeting of the Company. The Company has fixed Friday, July 19, 2024 as the Record Date for determining entitlement of Members to final dividend for the financial year ended March 31, 2024. The dividend, if approved by the shareholders will be paid on or after August 13, 2024.お知らせ • Apr 12Abbott India Limited Appoints Murari Ranganathan as Commercial DirectorAbbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Murari Ranganathan as Commercial Director - Women's Health, Metabolics and International Business effective May 2, 2024. He will be part of the Senior Management team of the Company. Murari Ranganathan is currently Commercial Director - Abbott Specialty Care (ASC) - Diabetes and Derma at Abbott Healthcare Private Limited. Murari joined Abbott in 2010 as Head Sales - Medical Nutrition and was successfully transitioned to Marketing Manager role in Specialty Care Metabolics and Urology in 2014. Over the years, he gained rich experience of managing various geographies and therapies. In 2015, he was promoted as Associate Director Vaccines, Abbott India Limited (AIL) and in 2018 he was given responsibility to lead the Commercial businesses of Metabolics and Miliana in AIL. Post his successful stint in AIL, he was appointed as Associate Director, ASC - Diabetes in 2020, and was then promoted as Commercial Director, ASC - Diabetes and Derma in 2021. In the past, Murari has worked with organizations like Baxter, Novo Nordisk and Torrent Pharma in various Sales and International Business roles. Murari has diverse experience building strong market presence in highly competitive areas such as Vaccines, Metabolics, Diabetes, and Nutrition. In his role, he has been instrumental in building brand portfolios, delivering market-beating growth, and setting up a compelling long-term vision aligned to the business strategy. Murari is a bachelor in physics and mathematics from Bangalore University and completed his post graduate diploma in Marketing from St Joseph College of Business Administration, Bangalore.Board Change • Apr 11Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Mar 29Price target increased by 10% to ₹27,242Up from ₹24,668, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of ₹26,946. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₹558 for next year compared to ₹447 last year.お知らせ • Mar 15Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024Abbott India Limited announced that Mr. Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business has tendered his resignation from employment of the Company with effect from June 5, 2024, to pursue an opportunity outside the Company. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective the said date.お知らせ • Jan 19Abbott India Limited to Report Q3, 2024 Results on Feb 01, 2024Abbott India Limited announced that they will report Q3, 2024 results on Feb 01, 2024お知らせ • Dec 19+ 1 more updateAbbott India Limited Announces Resignation of Vivek V Kamath as Managing Director, Effective from March 18, 2024Abbott India Limited informed that Mr. Vivek V Kamath (DIN: 06606777), has tendered his resignation as Managing Director of the Company, effective close of business hours of March 18, 2024, to pursue other opportunities outside the Company.Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹147 (vs ₹125 in 2Q 2023)Second quarter 2024 results: EPS: ₹147 (up from ₹125 in 2Q 2023). Revenue: ₹15.5b (up 12% from 2Q 2023). Net income: ₹3.13b (up 18% from 2Q 2023). Profit margin: 20% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.お知らせ • Nov 02Abbott India Limited to Report Q2, 2024 Results on Nov 09, 2023Abbott India Limited announced that they will report Q2, 2024 results on Nov 09, 2023お知らせ • Aug 10Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023Abbott India Limited announced at the board meeting held on August 9, 2023, approved appointment of Ms Sangeeta Shetty as Company Secretary and Compliance Officer of the Company effective September 14, 2023. Sangeeta has around two decades of experience in Corporate Secretarial, Compliance, Regulatory and Investor Relations functions. She has in-depth knowledge of Company Law, SEBI Regulations, Stock Exchange Listing Compliances, Corporate and Securities Law, Stock Broking, Insurance, Stock Exchange Regulations, Contract Management and Corporate Compliances and Governance matters. She has expertise in legal drafting and documentation for mergers and corporate restructuring, due diligence, policy making, stakeholder management and implementing best Corporate Governance practices. Sangeeta is associated with Financial Services - Aditya Birla Group. She was the Company Secretary and Compliance Officer of Aditya Birla Money Limited (August 2018 upto January 2022) and Aditya Birla Sun Life Insurance Company Limited (from January 2022 till date). She played a significant role in ensuring and monitoring compliances with the listing, insurance, stock broking, portfolio management and depository participant regulations. She has been earlier associated with Edelweiss Financial Services, Angel One and Metropolitan Stock Exchange of India. Sangeeta holds a bachelor's degree in Commerce and is a member of the Institute of Company Secretaries of India (ICSI). She also holds certification by ICSI on Commercial Contract Management and Foreign Exchange Management.New Risk • Aug 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.お知らせ • Jul 29Abbott India Limited to Report Q1, 2024 Results on Aug 09, 2023Abbott India Limited announced that they will report Q1, 2024 results on Aug 09, 2023お知らせ • Jul 25Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023Abbott India Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Ms Richa Tripathi as Associate Director - Sales Force Effectiveness (SFE) and Project Management Office (PMO) effective August 3, 2023. She will be part of the Senior Management team of the Company. Richa has close to 12 years of experience as a strategy, growth, and business transformation professional. She is joining the Company from Accenture, where she has worked for 4+ years as a strategy consultant within the Pharma and FMCG space. Prior to that she spent close to 5 years with Cipla across 3 key roles - Marketing Strategy, M&A and GCEO and MD's Office (Strategic projects). Her core skill lies in evaluating business needs and subsequently designing and implementing sustainable solutions through cross-functional collaborations with internal and external stakeholders to drive growth. She has built a strong acumen in functional areas like portfolio strategy, business expansion, spend strategy, route-to-market, and market entry as well as M&A deals for business diversification and streamlining while leading diverse teams towards successful results across her projects. Richa is an engineering graduate from VJTI with a Master's degree in Management from ISB Hyderabad.Reported Earnings • Jul 18Full year 2023 earnings released: EPS: ₹447 (vs ₹376 in FY 2022)Full year 2023 results: EPS: ₹447 (up from ₹376 in FY 2022). Revenue: ₹53.5b (up 8.9% from FY 2022). Net income: ₹9.49b (up 19% from FY 2022). Profit margin: 18% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 10 Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.Upcoming Dividend • Jul 14Upcoming dividend of ₹325 per share at 1.4% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (1.0%).Board Change • Jul 04Less than half of directors are independentFollowing Additional Non-Executive Director Mahadeo Karnik's arrival on 01 July 2023, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • May 21Full year 2023 earnings released: EPS: ₹447 (vs ₹376 in FY 2022)Full year 2023 results: EPS: ₹447 (up from ₹376 in FY 2022). Revenue: ₹55.0b (up 12% from FY 2022). Net income: ₹9.49b (up 19% from FY 2022). Profit margin: 17% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • May 20+ 4 more updatesAbbott India Limited, Annual General Meeting, Aug 09, 2023Abbott India Limited, Annual General Meeting, Aug 09, 2023. Agenda: To consider final dividend for the year ended March 31, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹116 (vs ₹93.74 in 3Q 2022)Third quarter 2023 results: EPS: ₹116 (up from ₹93.74 in 3Q 2022). Revenue: ₹13.3b (up 8.3% from 3Q 2022). Net income: ₹2.47b (up 24% from 3Q 2022). Profit margin: 19% (up from 16% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.お知らせ • Jan 31Abbott India Limited to Report Q3, 2023 Results on Feb 10, 2023Abbott India Limited announced that they will report Q3, 2023 results on Feb 10, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 05Abbott India Limited to Report Q2, 2023 Results on Nov 14, 2022Abbott India Limited announced that they will report Q2, 2023 results on Nov 14, 2022お知らせ • Aug 11+ 1 more updateAbbott India Limited Approves Final Dividend for the Financial Year Ended March 31, 2022Abbott India Limited approved final dividend of INR 145 per Equity Share for the financial year ended March 31, 2022, at the AGM held on August 10, 2022.お知らせ • Jul 30Abbott India Limited to Report Q1, 2023 Results on Aug 10, 2022Abbott India Limited announced that they will report Q1, 2023 results on Aug 10, 2022Upcoming Dividend • Jul 26Upcoming dividend of ₹275 per shareEligible shareholders must have bought the stock before 02 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.0%).Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹376 (vs ₹325 in FY 2021)Full year 2022 results: EPS: ₹376 (up from ₹325 in FY 2021). Revenue: ₹49.2b (up 14% from FY 2021). Net income: ₹7.99b (up 16% from FY 2021). Profit margin: 16% (in line with FY 2021). Post-clinical trial products Launched (during full year): 10 Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 19Abbott India Limited, Annual General Meeting, Aug 10, 2022Abbott India Limited, Annual General Meeting, Aug 10, 2022, at 09:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2022 together with the Reports of Directors and Auditors thereon; to declare a final dividend of 145 rupees and special dividend of 130 Rupees per Equity Share for the financial year ended March 31, 2022; to appoint a Director in place of Mr Ambati Venu, who retires by rotation and being eligible, offers himself for re-appointment; and to consider other matters.Reported Earnings • May 19Full year 2022 earnings released: EPS: ₹376 (vs ₹325 in FY 2021)Full year 2022 results: EPS: ₹376 (up from ₹325 in FY 2021). Revenue: ₹49.2b (up 14% from FY 2021). Net income: ₹7.99b (up 16% from FY 2021). Profit margin: 16% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 18+ 1 more updateAbbott India Limited Recommends Special Dividend for the Year Ended March 31, 2022Abbott India Limited announced that Board of Directors recommended special dividend of INR 130 per equity share for the year ended March 31, 2022, subject to approval by the Shareholders at the Annual General Meeting to be held on August 10, 2022.お知らせ • May 07Abbott India Limited to Report Q4, 2022 Results on May 17, 2022Abbott India Limited announced that they will report Q4, 2022 results on May 17, 2022Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 10+ 1 more updateAbbott India Limited Appoints Vivek V Kamath as Additional DirectorAbbott India Limited appointed Mr. Vivek V Kamath as additional director of the company for a term of 5 years with effect from February 15, 2022, subject to the approval by the shareholders of the company. Vivek is also appointed as the key managerial personnel of the company effective from February 15, 2022. Since September 2019, Vivek has been working with Abbott Healthcare Private Limited as general manager of the specialty care business. Prior to Abbott, worked with MSD Pharmaceuticals; Roche Diagnostics, India; Novartis, Singapore; Ranbaxy; Pfizer, India; Fulford, India; Wockhardt and Johnson & Johnson.Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹93.74 (up from ₹83.36 in 3Q 2021). Revenue: ₹12.2b (up 12% from 3Q 2021). Net income: ₹1.99b (up 13% from 3Q 2021). Profit margin: 16% (in line with 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 01Abbott India Limited to Report Q3, 2022 Results on Feb 09, 2022Abbott India Limited announced that they will report Q3, 2022 results on Feb 09, 2022Price Target Changed • Nov 16Price target increased to ₹19,998Up from ₹18,616, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹19,816. Stock is up 30% over the past year. The company posted earnings per share of ₹325 last year.株主還元500488IN PharmaceuticalsIN 市場7D-1.0%0.9%-0.08%1Y-16.9%16.9%4.6%株主還元を見る業界別リターン: 500488過去 1 年間で16.9 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 500488は、過去 1 年間で4.6 % のリターンを上げたIndian市場を下回りました。価格変動Is 500488's price volatile compared to industry and market?500488 volatility500488 Average Weekly Movement2.6%Pharmaceuticals Industry Average Movement6.1%Market Average Movement5.9%10% most volatile stocks in IN Market8.9%10% least volatile stocks in IN Market3.6%安定した株価: 500488 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 500488の 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19103,679Kartik Rajendranwww.abbott.co.inアボット・インディア・リミテッドは、その子会社とともにインドで製薬会社として事業を展開している。消化器、女性の健康、代謝、中枢神経、ワクチン、不眠症、ビタミンD欠乏症、早産、疼痛管理などのマルチスペシャリティ向け医薬品を提供。抗感染症、心臓糖尿病、肝臓、ホルモン、神経精神、肝臓、ジェネクスト、コンシューマーケア製品を提供。同社は1910年に設立され、インドのムンバイに本社を置いている。アボット・インディアはアボット・キャピタル・インディアの子会社。もっと見るAbbott India Limited 基礎のまとめAbbott India の収益と売上を時価総額と比較するとどうか。500488 基礎統計学時価総額₹586.85b収益（TTM）₹15.52b売上高(TTM)₹69.29b37.8xPER（株価収益率8.5xP/Sレシオ500488 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計500488 損益計算書（TTM）収益₹69.29b売上原価₹37.06b売上総利益₹32.23bその他の費用₹16.71b収益₹15.52b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）730.39グロス・マージン46.52%純利益率22.40%有利子負債／自己資本比率0%500488 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.9%現在の配当利回り72%配当性向500488 配当は確実ですか？500488 配当履歴とベンチマークを見る500488 、いつまでに購入すれば配当金を受け取れますか？Abbott India 配当日配当落ち日Jul 24 2026配当支払日Sep 12 2026配当落ちまでの日数21 days配当支払日までの日数29 days500488 配当は確実ですか？500488 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/13 23:04終値2026/08/13 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abbott India Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedAbdulkader PuranwalaAnand Rathi Shares and Stock Brokers LimitedNithya BalasubramanianBernstein12 その他のアナリストを表示
お知らせ • 4hAbbott India Limited Announces Board ChangesAbbott India Limited announced contribution of Mr. Munir Shaikh outgoing as Chairman of the Company. Mr. Sudarshan Jain had been appointed as Chairman of the Board with effect from August 13, 2026.
お知らせ • Aug 04Abbott India Limited to Report Q1, 2027 Results on Aug 12, 2026Abbott India Limited announced that they will report Q1, 2027 results on Aug 12, 2026
Reported Earnings • Jul 22Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹69.3b (up 8.1% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 20+ 2 more updatesAbbott India Limited Announces Retirement of Munir Shaikh as DirectorAbbott India Limited announced that Mr. Munir Shaikh, who retires by rotation at this Annual General Meeting and who has not offered himself for re-appointment, be and is hereby not re-appointed as a Director of the Company and the vacancy, so created, be not filled.
Upcoming Dividend • Jul 17Upcoming dividend of ₹656 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 12 September 2026. Payout ratio is a comfortable 72% and the cash payout ratio is 87%. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).
Declared Dividend • May 14Dividend increased to ₹525Dividend of ₹525 is 11% higher than last year. Ex-date: 24th July 2026 Payment date: 12th September 2026 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (71% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 31% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • 4hAbbott India Limited Announces Board ChangesAbbott India Limited announced contribution of Mr. Munir Shaikh outgoing as Chairman of the Company. Mr. Sudarshan Jain had been appointed as Chairman of the Board with effect from August 13, 2026.
お知らせ • Aug 04Abbott India Limited to Report Q1, 2027 Results on Aug 12, 2026Abbott India Limited announced that they will report Q1, 2027 results on Aug 12, 2026
Reported Earnings • Jul 22Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹69.3b (up 8.1% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 20+ 2 more updatesAbbott India Limited Announces Retirement of Munir Shaikh as DirectorAbbott India Limited announced that Mr. Munir Shaikh, who retires by rotation at this Annual General Meeting and who has not offered himself for re-appointment, be and is hereby not re-appointed as a Director of the Company and the vacancy, so created, be not filled.
Upcoming Dividend • Jul 17Upcoming dividend of ₹656 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 12 September 2026. Payout ratio is a comfortable 72% and the cash payout ratio is 87%. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%).
Declared Dividend • May 14Dividend increased to ₹525Dividend of ₹525 is 11% higher than last year. Ex-date: 24th July 2026 Payment date: 12th September 2026 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (71% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 31% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 13Abbott India Limited announces Annual dividend, payable on September 12, 2026Abbott India Limited announced Annual dividend of INR 525.0000 per share payable on September 12, 2026, ex-date on July 24, 2026 and record date on July 24, 2026.
お知らせ • May 12Abbott India Limited, Annual General Meeting, Aug 13, 2026Abbott India Limited, Annual General Meeting, Aug 13, 2026.
Reported Earnings • May 12Full year 2026 earnings released: EPS: ₹730 (vs ₹666 in FY 2025)Full year 2026 results: EPS: ₹730 (up from ₹666 in FY 2025). Revenue: ₹72.2b (up 13% from FY 2025). Net income: ₹15.5b (up 9.7% from FY 2025). Profit margin: 22% (in line with FY 2025). Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • May 02Abbott India Limited to Report Q4, 2026 Results on May 11, 2026Abbott India Limited announced that they will report Q4, 2026 results on May 11, 2026
Reported Earnings • Feb 13Third quarter 2026 earnings released: EPS: ₹177 (vs ₹170 in 3Q 2025)Third quarter 2026 results: EPS: ₹177 (up from ₹170 in 3Q 2025). Revenue: ₹17.9b (up 11% from 3Q 2025). Net income: ₹3.76b (up 4.2% from 3Q 2025). Profit margin: 21% (down from 22% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 04Abbott India Limited to Report Q3, 2026 Results on Feb 12, 2026Abbott India Limited announced that they will report Q3, 2026 results on Feb 12, 2026
New Risk • Nov 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Dividend is not well covered by cash flows (100% cash payout ratio).
Reported Earnings • Nov 07Second quarter 2026 earnings released: EPS: ₹195 (vs ₹169 in 2Q 2025)Second quarter 2026 results: EPS: ₹195 (up from ₹169 in 2Q 2025). Revenue: ₹18.3b (up 12% from 2Q 2025). Net income: ₹4.15b (up 16% from 2Q 2025). Profit margin: 23% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 14% per year.
お知らせ • Oct 29Abbott India Limited to Report Q2, 2026 Results on Nov 06, 2025Abbott India Limited announced that they will report Q2, 2026 results on Nov 06, 2025
Board Change • Sep 10Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 05Abbott India Limited to Report Q1, 2026 Results on Aug 12, 2025Abbott India Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Reported Earnings • Jul 24Full year 2025 earnings released: EPS: ₹666 (vs ₹565 in FY 2024)Full year 2025 results: EPS: ₹666 (up from ₹565 in FY 2024). Revenue: ₹64.1b (up 9.6% from FY 2024). Net income: ₹14.1b (up 18% from FY 2024). Profit margin: 22% (up from 21% in FY 2024). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 7 Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 21% per year.
Upcoming Dividend • Jul 18Upcoming dividend of ₹475 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 12 September 2025. Payout ratio is a comfortable 71% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.8%).
Board Change • Jun 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Additional Non-Executive Director Alison Davies was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • May 17Dividend increased to ₹475Dividend of ₹475 is 16% higher than last year. Ex-date: 25th July 2025 Payment date: 12th September 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not adequately covered by cash flows (91% cash payout ratio). The dividend has increased by an average of 37% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 24% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 16+ 1 more updateAbbott India Limited, Annual General Meeting, Aug 13, 2025Abbott India Limited, Annual General Meeting, Aug 13, 2025.
Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹666 (vs ₹565 in FY 2024)Full year 2025 results: EPS: ₹666 (up from ₹565 in FY 2024). Revenue: ₹66.8b (up 14% from FY 2024). Net income: ₹14.1b (up 18% from FY 2024). Profit margin: 21% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.
お知らせ • May 09Abbott India Limited to Report Fiscal Year 2025 Results on May 15, 2025Abbott India Limited announced that they will report fiscal year 2025 results on May 15, 2025
Price Target Changed • May 07Price target increased by 8.8% to ₹32,470Up from ₹29,839, the current price target is an average from 7 analysts. New target price is 7.3% above last closing price of ₹30,260. Stock is up 17% over the past year. The company is forecast to post earnings per share of ₹656 for next year compared to ₹565 last year.
お知らせ • Apr 19Abbott India Limited Appoints Maithilee Mistry as the Key Managerial Personnel, Effective May 6, 2025Abbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors at its Meeting held on April 18, 2025, approved the appointment of Ms. Maithilee Mistry as the Key Managerial Personnel of the Company effective May 6, 2025. Maithilee Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years, having held leadership roles in various Multinational companies. Previously Maithilee held a role of CFO for Sanofi Consumer Healthcare India Limited. Prior to that, she worked with Dow chemical in USA as global Funding Director, responsible for all aspects of corporate funding and banking relations. Before relocating to USA, she was Finance Director for Dow Chemical, India subcontinent region. Maithilee has also served as Board member in various companies including a public listed entity and other joint ventures in India. Before Joining Dow, she has also held leadership positions with Omya and Cognis, European multinational companies, leading teams in India and Southwest Asia with responsibilities for Finance, HR, Legal and IT. She is a qualified Chartered Accountant who started her career with Deloitte (India) as a member of statutory audit team. Ms. Maithilee Mistry is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company.
お知らせ • Apr 17Abbott India Limited Announces the Resignation of Ms. Namita Shah - Associate Director -New Product Introduction and Therapy Area Strategy of the Company, Effective from April 15, 2025Abbott India Limited announced the resignation of Ms. Namita Shah - Associate Director -New Product Introduction and Therapy Area Strategy of the Company, effective close of business hours of April 15, 2025, to pursue opportunities outside the Company.
お知らせ • Apr 01Abbott India Limited Appoints Devesh Choudhari as Director - Finance, Effective April 1, 2025Abbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Devesh Choudhari as Director - Finance effective April 1, 2025. He will be part of the Senior Management team of the Company. Mr. Devesh Choudhari is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company. Devesh Choudhari is a seasoned finance professional specializing in Finance, Accounting, Structuring, M&A, Fundraising, and Controls and has 18 years of experience. He brings a wealth of knowledge and a proven track record in leading complex financial projects. In his most recent role, Devesh joined Perfect Day, to lead their Indian manufacturing business following the acquisition of Sterling Biotech. As CFO, he played a key role in driving the business performance and contributed to the groundwork for a $100 million greenfield project currently under construction. Devesh actively contributed to the strategic sale and played a pivotal role in forming the joint venture with the Zydus group, later serving as its CFO. Prior to this, Devesh spent nearly a decade at the Piramal Group, gaining hands-on experience in multi-segment, multi-location manufacturing setups, as well as equity raises totaling over $1.5 billion. He significantly contributed to the $4 billion DHFL acquisition by Piramal and efficiently managed the integration of its financial operations. Earlier in his career, he worked with Deloitte in the Assurance function, handling leading FMCG, Chemical, and pharmaceutical companies. Devesh is a qualified Chartered Accountant and has done a Diploma in International Financial Reporting Standards (IFRS).
お知らせ • Mar 26Abbott India Limited Announces Resignation of Jyoti Saraph, Director Finance, with Effect from June 23, 2025Abbott India Limited informed that Ms. Jyoti Saraph, Director Finance, has tendered her resignation from employment of the Company with effect from the close of business hours of June 23, 2025, to pursue opportunities outside the Company.
Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹170 (vs ₹146 in 3Q 2024)Third quarter 2025 results: EPS: ₹170 (up from ₹146 in 3Q 2024). Revenue: ₹16.1b (up 12% from 3Q 2024). Net income: ₹3.61b (up 16% from 3Q 2024). Profit margin: 22% (in line with 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 21% per year.
お知らせ • Feb 03Abbott India Limited Announces Board ChangesAbbott India Limited informed that Mr. Kunal Chowdhury - Commercial Director - GI Businesses has been promoted to another affiliate of Abbott in India effective February 1, 2025. Accordingly,he has served his role as Commercial Director - GI Businesses with Abbott India Limited until January 31, 2025.
お知らせ • Jan 28Abbott India Limited to Report Q3, 2025 Results on Feb 05, 2025Abbott India Limited announced that they will report Q3, 2025 results on Feb 05, 2025
お知らせ • Jan 21Abbott India Limited Announces Kunal Chowdhury - Commercial Director - GI Businesses, to Serve Until January 31, 2025Abbott India Limited informed that Mr. Kunal Chowdhury - Commercial Director - GI Businesses has been promoted to another affiliate of Abbott in India effective February 1, 2025. He will serve his role as Commercial Director - GI Businesses with Abbott India Limited until January 31, 2025.
お知らせ • Jan 16Abbott India Limited Appoints Anuj Mehra as Commercial Director - Neurolife, Gennext and Vaccines, Effective February 1, 2025Abbott India Limited announced that Mr. Anuj Mehra, Senior Management Personnel, has been designated as Commercial Director - NeuroLife, GenNext and Vaccines effective February 1, 2025. Anuj is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company. Anuj Mehra has over 26 years of experience in Sales and Marketing in companies of diverse sizes. He has held leadership roles in Sales, Marketing, and Strategic planning. Anuj joined Abbott in 2018 as Head of Marketing for NeuroLife. Since then, Anuj has grown within the system by successfully managing various roles as Associate Director for Neurolife and is currently working as Associate Director of GenNext. Anuj has been instrumental in building a brand portfolio and driving business with robust strategic and operational excellence. Anuj, with his diverse experience, is able to think through and leverage growth opportunities in the operating segment by devising market-shaping initiatives. He has the ability to build robust business models to support business strategy and execute them. In the past, Anuj has worked with organizations like Sandoz, Ranbaxy, UCB, and Novartis. Anuj has a Bachelor's degree in Science from Delhi University and a Post Graduate Diploma in Business Management from SVKM's Narsee Monjee Institute of Management Studies (NMIMS).
お知らせ • Jan 03Abbott India Limited Announces Change of Commercial DirectorAbbott India Limited announced that Murari Ranganathan, Commercial Director - Women's Health, Metabolics and International Business, has tendered his resignation from employment of the Company with effect from close of business hours of February 25, 2025, to pursue opportunities outside the Company. Prithwish Kumar Banerji has been appointed as Commercial Director - Women's Health, Metabolics and International Business with effect from January 3, 2025. In accordance with the SEBI Listing Regulations, Prithwish will be considered as Senior Management Personnel of the Company. Prithwish has close to 28 years of experience in a Commercia role. He joins Abbott from Cipla, where he was a member of the Cipla Leadership Group. He was the designated Vice President and Vertical head for their respiratory portfolio of Nebulization and Immunotherapy. Prithwish presents a blended experience in Sales, Marketing, Strategic Business Planning and Execution. Prior to Cipla, Prithwish worked across Pharma MNCs and FMCG organizations like Unilever and GSK Consumer Healthcare. In the past, Prithwish had a small stint with Abbott Diabetes Care business as National Sales Manager. Prithwish has proven success in establishing new entrants in the Indian Pharmaceutical Market, Patent Product Launches, and Go-to-Market models, creating winners across the industry spectrum - Pharmaceuticals, OTC/OTX, and FMCG. Prithwish is a Honors graduate in Geology from St Xavier's College, Ranchi, and holds an Executive Management Program in Management from IIM Lucknow.
お知らせ • Dec 19+ 1 more updateAbbott India Limited Announces Resignation of Sridhar Kadangode as Whole Time Director and DirectorAbbott India Limited announced that Mr. Sridhar Kadangode, has tendered his resignation as Whole Time Director and Director of the Company, effective close of business hours of December 16, 2024, which has been accepted by the Board of Directors.
Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: ₹169 (vs ₹147 in 2Q 2024)Second quarter 2025 results: EPS: ₹169 (up from ₹147 in 2Q 2024). Revenue: ₹16.9b (up 13% from 2Q 2024). Net income: ₹3.59b (up 15% from 2Q 2024). Profit margin: 21% (in line with 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 07Abbott India Limited Appoints Mr. Sridhar Kadangode as an Additional Director and as the Whole Time Director of the CompanyAbbott India Limited Approved the appointment of Mr. Sridhar Kadangode (DIN: 06715478) as an Additional Director of the Company and as the Whole Time Director of the Company for a period of 2 (two) years with effect from November 7, 2024. Sridhar has overall 25 years of diversified experience in Finance and other functions and joined Abbott in 2014. Prior to being promoted as Group Finance Director and Chief Financial Officer of the Company in July 2023, Sridhar was the Director - Finance of the Company responsible for finance, demand planning and business compliance function. Under his leadership, the Company recorded a strong financial performance through the pandemic, both in topline and bottom line and continued to focus on future growth. He has also redesigned the 5-year strategic financial plan for the Company. He drove a leveraged PL for the Company which resulted in Topline growing higher than market and a significantly improved bottom line for 2023-24. Sridhar started his career with Abbott as Director Finance, ANI and was part of the Core Management Team which evolved the Path to Profitability for the Nutrition business for South Asia which included achieving significant improvement in bottom line. He has led some of the key business projects linked to business response during Demonetization, Distributor Optimization and Cost Leadership Initiatives. Sridhar started his professional journey with Britannia Industries and then moved to Group Danone where he handled multiple assignments overseas (Singapore, US, Malaysia, South Africa) before relocating back to India in 2011 and in these companies, he was responsible for Finance, Supply Chain and Procurement functions. His key accomplishments with Danone include Reorganization of Business Model, Implementation of Supply Chain efficiency projects and transformation of Finance function into a key business partner in driving the business. Sridhar is a qualified Chartered Accountant from Institute of Chartered Accountants of India and Cost Accountant from Institute of Cost Accountants of India.
お知らせ • Oct 29Abbott India Limited to Report Q2, 2025 Results on Nov 07, 2024Abbott India Limited announced that they will report Q2, 2025 results on Nov 07, 2024
お知らせ • Aug 09Abbott India Limited Approves Final Dividend for Financial Year Ended March 31, 2024Abbott India Limited at its AGM held on August 08, 2024, approved to declare a final dividend of INR 410/- per Equity Share for the financial year ended March 31, 2024.
お知らせ • Jul 30Abbott India Limited to Report Q1, 2025 Results on Aug 07, 2024Abbott India Limited announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • Jul 17Abbott India Limited Announces Resignation of Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife, Effective October 16, 2024Abbott India Limited informed that Mr. Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife has tendered his resignation from employment of the Company with effect from October 16, 2024, for personal reasons. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective October 16, 2024.
Board Change • Jul 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 14Full year 2024 earnings released: EPS: ₹565 (vs ₹447 in FY 2023)Full year 2024 results: EPS: ₹565 (up from ₹447 in FY 2023). Revenue: ₹58.5b (up 9.4% from FY 2023). Net income: ₹12.0b (up 27% from FY 2023). Profit margin: 21% (up from 18% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 8 Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year.
Upcoming Dividend • Jul 12Upcoming dividend of ₹410 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 07 September 2024. Payout ratio is a comfortable 73% and this is well supported by cash flows. Trailing yield: 1.5%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%).
お知らせ • Jun 13Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024Abbott India Limited announced resignation of Ms. Sabina Ewing as Director of the Company, effective close of business hours of June 12, 2024, due to her pre-occupation with other professional commitments.
お知らせ • May 12Abbott India Limited, Annual General Meeting, Aug 08, 2024Abbott India Limited, Annual General Meeting, Aug 08, 2024.
Reported Earnings • May 11Full year 2024 earnings released: EPS: ₹565 (vs ₹447 in FY 2023)Full year 2024 results: EPS: ₹565 (up from ₹447 in FY 2023). Revenue: ₹61.0b (up 14% from FY 2023). Net income: ₹12.0b (up 27% from FY 2023). Profit margin: 20% (up from 18% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 18% per year.
Declared Dividend • May 11Dividend increased to ₹410Dividend of ₹410 is 26% higher than last year. Ex-date: 19th July 2024 Payment date: 7th September 2024 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (40% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 34% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 35% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 11Abbott India Limited Recommends Final Dividend for the Year Ended March 31, 2024, Payable on or After August 13, 2024Abbott India Limited recommended payment of final dividend of INR 410/- per equity share of INR 10/- each for the year ended March 31, 2024, subject To Approve the Shareholders at the ensuing Eightieth Annual General Meeting of the Company. The Company has fixed Friday, July 19, 2024 as the Record Date for determining entitlement of Members to final dividend for the financial year ended March 31, 2024. The dividend, if approved by the shareholders will be paid on or after August 13, 2024.
お知らせ • Apr 12Abbott India Limited Appoints Murari Ranganathan as Commercial DirectorAbbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Murari Ranganathan as Commercial Director - Women's Health, Metabolics and International Business effective May 2, 2024. He will be part of the Senior Management team of the Company. Murari Ranganathan is currently Commercial Director - Abbott Specialty Care (ASC) - Diabetes and Derma at Abbott Healthcare Private Limited. Murari joined Abbott in 2010 as Head Sales - Medical Nutrition and was successfully transitioned to Marketing Manager role in Specialty Care Metabolics and Urology in 2014. Over the years, he gained rich experience of managing various geographies and therapies. In 2015, he was promoted as Associate Director Vaccines, Abbott India Limited (AIL) and in 2018 he was given responsibility to lead the Commercial businesses of Metabolics and Miliana in AIL. Post his successful stint in AIL, he was appointed as Associate Director, ASC - Diabetes in 2020, and was then promoted as Commercial Director, ASC - Diabetes and Derma in 2021. In the past, Murari has worked with organizations like Baxter, Novo Nordisk and Torrent Pharma in various Sales and International Business roles. Murari has diverse experience building strong market presence in highly competitive areas such as Vaccines, Metabolics, Diabetes, and Nutrition. In his role, he has been instrumental in building brand portfolios, delivering market-beating growth, and setting up a compelling long-term vision aligned to the business strategy. Murari is a bachelor in physics and mathematics from Bangalore University and completed his post graduate diploma in Marketing from St Joseph College of Business Administration, Bangalore.
Board Change • Apr 11Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Mar 29Price target increased by 10% to ₹27,242Up from ₹24,668, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of ₹26,946. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₹558 for next year compared to ₹447 last year.
お知らせ • Mar 15Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024Abbott India Limited announced that Mr. Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business has tendered his resignation from employment of the Company with effect from June 5, 2024, to pursue an opportunity outside the Company. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective the said date.
お知らせ • Jan 19Abbott India Limited to Report Q3, 2024 Results on Feb 01, 2024Abbott India Limited announced that they will report Q3, 2024 results on Feb 01, 2024
お知らせ • Dec 19+ 1 more updateAbbott India Limited Announces Resignation of Vivek V Kamath as Managing Director, Effective from March 18, 2024Abbott India Limited informed that Mr. Vivek V Kamath (DIN: 06606777), has tendered his resignation as Managing Director of the Company, effective close of business hours of March 18, 2024, to pursue other opportunities outside the Company.
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹147 (vs ₹125 in 2Q 2023)Second quarter 2024 results: EPS: ₹147 (up from ₹125 in 2Q 2023). Revenue: ₹15.5b (up 12% from 2Q 2023). Net income: ₹3.13b (up 18% from 2Q 2023). Profit margin: 20% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.
お知らせ • Nov 02Abbott India Limited to Report Q2, 2024 Results on Nov 09, 2023Abbott India Limited announced that they will report Q2, 2024 results on Nov 09, 2023
お知らせ • Aug 10Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023Abbott India Limited announced at the board meeting held on August 9, 2023, approved appointment of Ms Sangeeta Shetty as Company Secretary and Compliance Officer of the Company effective September 14, 2023. Sangeeta has around two decades of experience in Corporate Secretarial, Compliance, Regulatory and Investor Relations functions. She has in-depth knowledge of Company Law, SEBI Regulations, Stock Exchange Listing Compliances, Corporate and Securities Law, Stock Broking, Insurance, Stock Exchange Regulations, Contract Management and Corporate Compliances and Governance matters. She has expertise in legal drafting and documentation for mergers and corporate restructuring, due diligence, policy making, stakeholder management and implementing best Corporate Governance practices. Sangeeta is associated with Financial Services - Aditya Birla Group. She was the Company Secretary and Compliance Officer of Aditya Birla Money Limited (August 2018 upto January 2022) and Aditya Birla Sun Life Insurance Company Limited (from January 2022 till date). She played a significant role in ensuring and monitoring compliances with the listing, insurance, stock broking, portfolio management and depository participant regulations. She has been earlier associated with Edelweiss Financial Services, Angel One and Metropolitan Stock Exchange of India. Sangeeta holds a bachelor's degree in Commerce and is a member of the Institute of Company Secretaries of India (ICSI). She also holds certification by ICSI on Commercial Contract Management and Foreign Exchange Management.
New Risk • Aug 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
お知らせ • Jul 29Abbott India Limited to Report Q1, 2024 Results on Aug 09, 2023Abbott India Limited announced that they will report Q1, 2024 results on Aug 09, 2023
お知らせ • Jul 25Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023Abbott India Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Ms Richa Tripathi as Associate Director - Sales Force Effectiveness (SFE) and Project Management Office (PMO) effective August 3, 2023. She will be part of the Senior Management team of the Company. Richa has close to 12 years of experience as a strategy, growth, and business transformation professional. She is joining the Company from Accenture, where she has worked for 4+ years as a strategy consultant within the Pharma and FMCG space. Prior to that she spent close to 5 years with Cipla across 3 key roles - Marketing Strategy, M&A and GCEO and MD's Office (Strategic projects). Her core skill lies in evaluating business needs and subsequently designing and implementing sustainable solutions through cross-functional collaborations with internal and external stakeholders to drive growth. She has built a strong acumen in functional areas like portfolio strategy, business expansion, spend strategy, route-to-market, and market entry as well as M&A deals for business diversification and streamlining while leading diverse teams towards successful results across her projects. Richa is an engineering graduate from VJTI with a Master's degree in Management from ISB Hyderabad.
Reported Earnings • Jul 18Full year 2023 earnings released: EPS: ₹447 (vs ₹376 in FY 2022)Full year 2023 results: EPS: ₹447 (up from ₹376 in FY 2022). Revenue: ₹53.5b (up 8.9% from FY 2022). Net income: ₹9.49b (up 19% from FY 2022). Profit margin: 18% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 10 Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.
Upcoming Dividend • Jul 14Upcoming dividend of ₹325 per share at 1.4% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (1.0%).
Board Change • Jul 04Less than half of directors are independentFollowing Additional Non-Executive Director Mahadeo Karnik's arrival on 01 July 2023, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 21Full year 2023 earnings released: EPS: ₹447 (vs ₹376 in FY 2022)Full year 2023 results: EPS: ₹447 (up from ₹376 in FY 2022). Revenue: ₹55.0b (up 12% from FY 2022). Net income: ₹9.49b (up 19% from FY 2022). Profit margin: 17% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • May 20+ 4 more updatesAbbott India Limited, Annual General Meeting, Aug 09, 2023Abbott India Limited, Annual General Meeting, Aug 09, 2023. Agenda: To consider final dividend for the year ended March 31, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹116 (vs ₹93.74 in 3Q 2022)Third quarter 2023 results: EPS: ₹116 (up from ₹93.74 in 3Q 2022). Revenue: ₹13.3b (up 8.3% from 3Q 2022). Net income: ₹2.47b (up 24% from 3Q 2022). Profit margin: 19% (up from 16% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.
お知らせ • Jan 31Abbott India Limited to Report Q3, 2023 Results on Feb 10, 2023Abbott India Limited announced that they will report Q3, 2023 results on Feb 10, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 05Abbott India Limited to Report Q2, 2023 Results on Nov 14, 2022Abbott India Limited announced that they will report Q2, 2023 results on Nov 14, 2022
お知らせ • Aug 11+ 1 more updateAbbott India Limited Approves Final Dividend for the Financial Year Ended March 31, 2022Abbott India Limited approved final dividend of INR 145 per Equity Share for the financial year ended March 31, 2022, at the AGM held on August 10, 2022.
お知らせ • Jul 30Abbott India Limited to Report Q1, 2023 Results on Aug 10, 2022Abbott India Limited announced that they will report Q1, 2023 results on Aug 10, 2022
Upcoming Dividend • Jul 26Upcoming dividend of ₹275 per shareEligible shareholders must have bought the stock before 02 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.0%).
Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹376 (vs ₹325 in FY 2021)Full year 2022 results: EPS: ₹376 (up from ₹325 in FY 2021). Revenue: ₹49.2b (up 14% from FY 2021). Net income: ₹7.99b (up 16% from FY 2021). Profit margin: 16% (in line with FY 2021). Post-clinical trial products Launched (during full year): 10 Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 19Abbott India Limited, Annual General Meeting, Aug 10, 2022Abbott India Limited, Annual General Meeting, Aug 10, 2022, at 09:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2022 together with the Reports of Directors and Auditors thereon; to declare a final dividend of 145 rupees and special dividend of 130 Rupees per Equity Share for the financial year ended March 31, 2022; to appoint a Director in place of Mr Ambati Venu, who retires by rotation and being eligible, offers himself for re-appointment; and to consider other matters.
Reported Earnings • May 19Full year 2022 earnings released: EPS: ₹376 (vs ₹325 in FY 2021)Full year 2022 results: EPS: ₹376 (up from ₹325 in FY 2021). Revenue: ₹49.2b (up 14% from FY 2021). Net income: ₹7.99b (up 16% from FY 2021). Profit margin: 16% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 18+ 1 more updateAbbott India Limited Recommends Special Dividend for the Year Ended March 31, 2022Abbott India Limited announced that Board of Directors recommended special dividend of INR 130 per equity share for the year ended March 31, 2022, subject to approval by the Shareholders at the Annual General Meeting to be held on August 10, 2022.
お知らせ • May 07Abbott India Limited to Report Q4, 2022 Results on May 17, 2022Abbott India Limited announced that they will report Q4, 2022 results on May 17, 2022
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Shalini Kamath was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 10+ 1 more updateAbbott India Limited Appoints Vivek V Kamath as Additional DirectorAbbott India Limited appointed Mr. Vivek V Kamath as additional director of the company for a term of 5 years with effect from February 15, 2022, subject to the approval by the shareholders of the company. Vivek is also appointed as the key managerial personnel of the company effective from February 15, 2022. Since September 2019, Vivek has been working with Abbott Healthcare Private Limited as general manager of the specialty care business. Prior to Abbott, worked with MSD Pharmaceuticals; Roche Diagnostics, India; Novartis, Singapore; Ranbaxy; Pfizer, India; Fulford, India; Wockhardt and Johnson & Johnson.
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹93.74 (up from ₹83.36 in 3Q 2021). Revenue: ₹12.2b (up 12% from 3Q 2021). Net income: ₹1.99b (up 13% from 3Q 2021). Profit margin: 16% (in line with 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 01Abbott India Limited to Report Q3, 2022 Results on Feb 09, 2022Abbott India Limited announced that they will report Q3, 2022 results on Feb 09, 2022
Price Target Changed • Nov 16Price target increased to ₹19,998Up from ₹18,616, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹19,816. Stock is up 30% over the past year. The company posted earnings per share of ₹325 last year.
